CF602
Erectile Dysfunction
PreclinicalActive
Key Facts
About Can Fite Biopharma
Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.
View full company profileTherapeutic Areas
Other Erectile Dysfunction Drugs
| Drug | Company | Phase |
|---|---|---|
| Sildenafil Formulation | InnovaZone Labs | Approved |
| Rigi10™ Malleable Penile Prosthesis | Rigicon | Approved |
| UNITED Study (Investigational Inflatable Penile Prosthesis) | Rigicon | Clinical Investigation |
| ASP-001 | Aspargo Laboratories | Approved |
| Sildenafil-loaded Z-pods® | Atticus Pharma | Pre-clinical |
| FGF-based Therapeutic | Venturis Therapeutics | Pre-clinical |
| DehydraTECH-sildenafil | Lexaria Bioscience | Human Clinical |